Clinical Trial Update: A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial of ATR-101 for endogenous Cushing's syndrome was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cushing Syndrome

Drugs mentioned

• ATR-101

Snippet

Sponsor: Millendo Therapeutics US, Inc. | Conditions: Cushing Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2021-03-02